医学
耐火材料(行星科学)
托法替尼
掌跖脓疱病
贾纳斯激酶
银屑病
皮肤病科
Janus激酶抑制剂
内科学
类风湿性关节炎
细胞因子
受体
天体生物学
物理
作者
Sonal Muzumdar,Craig L. Leonardi,Bruce Strober
出处
期刊:Journal of psoriasis and psoriatic arthritis
[SAGE]
日期:2021-02-22
卷期号:6 (2): 93-98
被引量:2
标识
DOI:10.1177/2475530321995516
摘要
Background: Palmoplantar psoriasis can severely impact patient quality of life. Despite the influx of many new medications, it remains one of the most challenging psoriasis phenotypes to treat. Case Description: Herein, we present a case series of 7 patients with hyperkeratotic palmoplantar psoriasis refractory to systemic therapy who were successfully treated with tofacitinib, a Janus kinase (JAK) 1/3 inhibitor. Conclusions: Tofacitinib may be an effective therapy for the management of recalcitrant palmoplantar psoriasis. The efficacy of tofacitinib for the treatment of palmoplantar psoriasis might clarify the dependence on this subtype of psoriasis on specific cytokines that signal through JAK 1/3.
科研通智能强力驱动
Strongly Powered by AbleSci AI